(R-(R*,S*))-3-(3-Cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidine-4-heptanoic acid (BioDeep_00000176903)

   

human metabolite blood metabolite Volatile Flavor Compounds


代谢物信息卡片


(R-(R*,S*))-3-(3-Cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidine-4-heptanoic acid

化学式: C19H32N2O5 (368.2311102)
中文名称: 4-咪唑烷庚酸，3-[（3R）-3-环己基-3-羟丙基]-2,5-二氧代-，（4R）-rel
谱图信息: 最多检出来源 Mus musculus(blood) 90%

分子结构信息

SMILES: C1CCC(CC1)C(CCN2C(C(=O)NC2=O)CCCCCCC(=O)O)O
InChI: InChI=1S/C19H32N2O5/c22-16(14-8-4-3-5-9-14)12-13-21-15(18(25)20-19(21)26)10-6-1-2-7-11-17(23)24/h14-16,22H,1-13H2,(H,23,24)(H,20,25,26)

描述信息

同义名列表

10 个代谢物同义名

(R-(R*,S*))-3-(3-Cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidine-4-heptanoic acid; (R-(R*,s*))-3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidine-4-heptanoate; 7-[3-(3-cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidin-4-yl]heptanoic acid; 7-[3-(3-Cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidin-4-yl]heptanoate; 3-(3-Cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidine-4-heptanoic acid; 3-(3-Cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidine-4-heptanoate; 5-(6-Carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl)hydantoin; BW 245C, (R*,s*)-(+-); BW-245C; 4-Imidazolidineheptanoic acid, 3-[(3R)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxo-, (4R)-rel-



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Nuria Maicas, Lidia Ibáñez, María José Alcaraz, Amalia Úbeda, María Luisa Ferrándiz. Prostaglandin D2 regulates joint inflammation and destruction in murine collagen-induced arthritis. Arthritis and rheumatism. 2012 Jan; 64(1):130-40. doi: 10.1002/art.30656. [PMID: 21898357]
  • David Torres, Christophe Paget, Josette Fontaine, Thierry Mallevaey, Toshiyuki Matsuoka, Takayuki Maruyama, Shuh Narumiya, Monique Capron, Philippe Gosset, Christelle Faveeuw, François Trottein. Prostaglandin D2 inhibits the production of IFN-gamma by invariant NK T cells: consequences in the control of B16 melanoma. Journal of immunology (Baltimore, Md. : 1950). 2008 Jan; 180(2):783-92. doi: 10.4049/jimmunol.180.2.783. [PMID: 18178816]
  • Kang Cheng, Tsuei-Ju Wu, Kenneth K Wu, Claudio Sturino, Kathleen Metters, Keith Gottesdiener, Samuel D Wright, Zhaoyin Wang, Gary O'Neill, Eseng Lai, M Gerard Waters. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proceedings of the National Academy of Sciences of the United States of America. 2006 Apr; 103(17):6682-7. doi: 10.1073/pnas.0601574103. [PMID: 16617107]
  • Kristin A Koch, Jerry L Wessale, Robert Moreland, Glenn A Reinhart, Bryan F Cox. Effects of BW245C, a prostaglandin dp receptor agonist, on systemic and regional haemodynamics in the anaesthetized rat. Clinical and experimental pharmacology & physiology. 2005 Nov; 32(11):931-5. doi: 10.1111/j.1440-1681.2005.04287.x. [PMID: 16405449]
  • Sarah J O'Meara, B Therese Kinsella. Effect of the statin atorvastatin on intracellular signalling by the prostacyclin receptor in vitro and in vivo. British journal of pharmacology. 2004 Sep; 143(2):292-302. doi: 10.1038/sj.bjp.0705947. [PMID: 15326037]
  • J F Foley, L P Kelley, B T Kinsella. Prostaglandin D(2) receptor-mediated desensitization of the alpha isoform of the human thromboxane A(2) receptor. Biochemical pharmacology. 2001 Jul; 62(2):229-39. doi: 10.1016/s0006-2952(01)00661-x. [PMID: 11389883]
  • D H Wright, F Nantel, K M Metters, A W Ford-Hutchinson. A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor. European journal of pharmacology. 1999 Jul; 377(1):101-15. doi: 10.1016/s0014-2999(99)00358-1. [PMID: 10448933]
  • D H Wright, K M Metters, M Abramovitz, A W Ford-Hutchinson. Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. British journal of pharmacology. 1998 Apr; 123(7):1317-24. doi: 10.1038/sj.bjp.0701708. [PMID: 9579725]
  • R J Keery, P Lumley. AH6809, a prostaglandin DP-receptor blocking drug on human platelets. British journal of pharmacology. 1988 Jul; 94(3):745-54. doi: 10.1111/j.1476-5381.1988.tb11584.x. [PMID: 2460179]
  • C H Bamford, I P Middleton, K G Al-Lamee. Polymeric inhibitors of platelet aggregation. Synergistic effects and proposals for a new mechanism. Biochimica et biophysica acta. 1986 Apr; 886(1):109-18. doi: 10.1016/0167-4889(86)90216-8. [PMID: 2420369]
  • Y Noda, R D Hughes, R Williams. Effect of prostacyclin (PGI2) and a prostaglandin analogue BW 245C on galactosamine-induced hepatic necrosis. Journal of hepatology. 1986; 2(1):53-64. doi: 10.1016/s0168-8278(86)80008-3. [PMID: 3512686]
  • S Hamid, B J Whittle. Interaction of prostaglandin D2 with prostacyclin, carbacyclin and the hydantoin prostaglandin, BW245C, in guinea-pig platelets. British journal of pharmacology. 1985 May; 85(1):285-90. doi: 10.1111/j.1476-5381.1985.tb08858.x. [PMID: 2992652]
  • M Zahavi, J Zahavi, V V Kakkar. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation. Thrombosis and haemostasis. 1984 Oct; 52(2):205-9. doi: 10.1055/s-0038-1661173. [PMID: 6098048]
  • B J Whittle, S Moncada, K Mullane, J R Vane. Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue. Prostaglandins. 1983 Feb; 25(2):205-23. doi: 10.1016/0090-6980(83)90105-3. [PMID: 6344147]